UPDATE : Friday, January 17, 2020
Biogen, Samsung Bioepis announce European launch of Imraldi
Biogen and Samsung Bioepis said Tuesday they will launch Imraldi, the compa...
by Lee Han-soo  |  2018-10-17 17:28
Bio stocks listed under ‘tech exception policy’ perform better
Biotech and medical companies that went public under the Korea Exchange’s “...
by Nam Doo-hyun  |  2018-10-15 12:27
Merck to supply Samsung’s biosimilar to US Veterans Affairs Dept.
Merck, known as MSD outside the United States and Canada, announced that is...
by Lee Han-soo  |  2018-10-11 16:31
US drug advisory recommends Celltrion’s Rituxan biosimilar for approval
Celltrion said Thursday that the U.S. Oncologic Drug Advisory Committee (OD...
by Lee Han-soo  |  2018-10-11 12:10
‘Korea publishes many biotech papers but rarely links them to biz’
South Korea’s ranking in biotech competitiveness, announced by the U.S. sci...
by Nam Doo-hyun  |  2018-10-10 16:35
GC opens new cell research center
GC said Monday that it has dedicated a new integrated research center in a ...
by Lee Han-soo  |  2018-10-10 11:45
More biotech stocks come in top 20 on KOSDAQ
The number of pharmaceutical and biotech firms within the top 20 companies ...
by Nam Doo-hyun  |  2018-10-10 11:20
Newly listed biotech firms perform poorly on KOSDAQ
Biotech companies that went public in the first half of this year have show...
by Nam Doo-hyun  |  2018-10-04 13:09
‘Samsung C&T’s value to rise on BioLogics’ increased value’
Samsung C&T Corp., the parent company of Samsung Group, is likely to enjoy ...
by Nam Doo-hyun  |  2018-10-03 10:11
More doctoral degree holders wanted at biotech ventures
Korean biotech venture companies are increasingly seeking more Ph.D.-qualif...
by Nam Doo-hyun  |  2018-10-02 14:40
FDA to review Samsung Bioepis’ application for anti-arthritis biosimilar
Samsung Bioepis said Thursday that the U.S. Food and Drug Administration ha...
by Lee Han-soo  |  2018-09-27 11:22
Biois registers patent to develop TNF-alpha inhibitor
Biois Corp. said it has registered a patent on aptamers binding to tumor ne...
by So Jae-hyeon  |  2018-09-20 16:45
Celltrion, Emory University to develop new drug for Atherosclerosis
Celltrion said Thursday that it has signed an “incubation” agreement with E...
by Lee Han-soo  |  2018-09-20 13:22
FDA approves Bifido’s strain as new dietary ingredient
Bifido, a local microbiome company, said Tuesday that the U.S. Food and Dru...
by Lee Han-soo  |  2018-09-18 17:14
Nature Cell shares spike despite investment alert warning
Industry watchers are looking for answers why shares of Nature Cell have be...
by Nam Doo-hyun  |  2018-09-14 16:08
GC Cell shares spike on winning FDA nod for Immuncell-LC
Stock prices of GC Cell and ToolGen went in the opposite direction on Wedne...
by Nam Doo-hyun  |  2018-09-12 16:05
‘Regulator’s scrutiny into ToolGen’s patent issue might discourage biotech research’
The biotech industry is paying close attention to how the recent controvers...
by So Jae-hyeon  |  2018-09-12 14:25
‘ToolGen’s KOSDAQ listing might be in peril’
ToolGen, a local biotech firm specialized in gene editing, has been mired i...
by Nam Doo-hyun  |  2018-09-10 14:59
‘Pharmaceutical stocks to bottom out soon’
Korean pharmaceutical and biotech shares are expected to have an upward tre...
by Nam Doo-hyun  |  2018-08-29 14:34
Celltrion completes P3 clinical trials for Remsima in Europe
Celltrion said it has completed phase 3 clinical trial for Remsima SC, the ...
by Lee Han-soo  |  2018-08-29 14:33
Back to Top